Jamie B. Spangler
Jamie B. Spangler
Assistant Professor, Johns Hopkins University
Verified email at - Homepage
Cited by
Cited by
De novo design of potent and selective mimics of IL-2 and IL-15
DA Silva, S Yu, UY Ulge, JB Spangler, KM Jude, C Lab„o-Almeida, LR Ali, ...
Nature 565 (7738), 186-191, 2019
Insights into cytokine–receptor interactions from cytokine engineering
JB Spangler, I Moraga, JL Mendoza, KC Garcia
Annual review of immunology 33, 139-167, 2015
Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms
JB Spangler, J Tomala, VC Luca, KM Jude, S Dong, AM Ring, P Votavova, ...
Immunity 42 (5), 815-825, 2015
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
JB Spangler, JR Neil, S Abramovitch, Y Yarden, FM White, ...
Proceedings of the National Academy of Sciences 107 (30), 13252-13257, 2010
Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps
S Mitra, AM Ring, S Amarnath, JB Spangler, P Li, W Ju, S Fischer, J Oh, ...
Immunity 42 (5), 826-838, 2015
Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells
CR Glassman, YK Mathiharan, KM Jude, L Su, O Panova, PJ Lupardus, ...
Cell 184 (4), 983-999. e24, 2021
Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers
I Moraga, JB Spangler, JL Mendoza, M Gakovic, TS Wehrman, P Krutzik, ...
Elife 6, e22882, 2017
Multifarious determinants of cytokine receptor signaling specificity
I Moraga, J Spangler, JL Mendoza, KC Garcia
Advances in immunology 121, 1-39, 2014
Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy
JB Spangler, E Trotta, J Tomala, A Peck, TA Young, CS Savvides, ...
The Journal of Immunology 201 (7), 2094-2106, 2018
Engineered proteins including mutant fibronectin domains
KD Wittrup, JB Spangler, BJ Hackel
US Patent App. 13/390,086, 2012
Engineering cytokine therapeutics
J Deckers, T Anbergen, AM Hokke, A de Dreu, DP Schrijver, K de Bruin, ...
Nature Reviews Bioengineering 1 (4), 286-303, 2023
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression
JB Spangler, MT Manzari, EK Rosalia, TF Chen, KD Wittrup
Journal of molecular biology 422 (4), 532-544, 2012
IgM autoantibodies recognizing ACE2 are associated with severe COVID-19
L Casciola-Rosen, DR Thiemann, F Andrade, MIT Zambrano, JE Hooper, ...
MedRxiv, 2020
Suspendable hydrogel nanovials for massively parallel single-cell functional analysis and sorting
J De Rutte, R Dimatteo, MM Archang, M Van Zee, D Koo, S Lee, ...
ACS nano 16 (5), 7242-7257, 2022
Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers
M You, J Spangler, E Li, X Han, P Ghosh, K Hristova
Biochemistry 46 (39), 11039-11046, 2007
Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications
T Iwamoto, M You, E Li, J Spangler, JM Tomich, K Hristova
Biochimica et Biophysica Acta (BBA)-Biomembranes 1668 (2), 240-247, 2005
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
A Quijano-Rubio, AM Bhuiyan, H Yang, I Leung, E Bello, LR Ali, ...
Nature biotechnology 41 (4), 532-540, 2023
IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function
L Casciola-Rosen, DR Thiemann, F Andrade, MI Trejo-Zambrano, ...
JCI insight 7 (9), 2022
Strategies for glycoengineering therapeutic proteins
K Dammen-Brower, P Epler, S Zhu, ZJ Bernstein, PR Stabach, ...
Frontiers in Chemistry 10, 863118, 2022
Engineered antibody fusion proteins for targeted disease therapy
AB Silver, EK Leonard, JR Gould, JB Spangler
Trends in pharmacological sciences 42 (12), 1064-1081, 2021
The system can't perform the operation now. Try again later.
Articles 1–20